SCIG Hizentra denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for scig hizentra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied SCIG / Hizentra as Experimental

Aetna's experimental or investigational denial for Hizentra (immune globulin subcutaneous, human) is likely the result of a policy-version mismatch, a non-standard indication, or an administrative review error. Hizentra has FDA approval for the treatment of primary immunodeficiency (PI) in adults and pediatric patients, and subcutaneous immunoglobulin therapy is supported by established professional society guidelines. When Hizentra is prescribed for its FDA-approved indication, an experimental classification is a reviewable administrative determination.

If, however, the prescription is for an off-label use — such as a neuromuscular condition or another indication for which SCIG is used in practice but has not received FDA approval for this product — Aetna's experimental classification may reflect a legitimate coverage boundary. Off-label use appeals are possible but require a higher standard of evidence documentation.

### Why This Denial Is Appealable

For on-label use, Aetna must apply its experimental/investigational criteria consistently, and an FDA-approved product used within its approved indication does not meet the standard definition of experimental. For off-label use, Aetna's coverage policy may extend to uses supported by recognized compendia (such as Drugdex or AHFS) or by major clinical practice guidelines; your prescriber should identify the applicable pathway. Either way, the denial triggers appeal rights.

### Federal Appeal Framework

• Internal appeal: File under ERISA §503 (employer plans) or ACA §2719 (individual/small-group plans) within the deadline on the denial notice.
• External review: ACA §2719 guarantees access to independent external review after an adverse internal decision. The external review window is typically approximately four months from the final internal denial — verify the exact deadline on your Explanation of Benefits.
• Expedited review: Primary immunodeficiency and related conditions can make timely immunoglobulin access medically urgent. Request expedited review in writing and have your prescriber document the clinical urgency explicitly.

### Concrete Appeal Steps

1. Determine whether the prescription is for an FDA-approved indication or an off-label use — the appeal strategy differs. 2. For on-label use: download the FDA-approved prescribing information for Hizentra and attach it to the appeal. Request that Aetna specify which element of its experimental criteria the drug fails. 3. For off-label use: ask your prescriber to identify supportive compendia listings or major society guidelines (naming the organization, not citing statistics) and to write a clinical letter explaining the evidence basis. 4. Gather diagnosis documentation and chart notes confirming the clinical indication. 5. Submit the internal appeal; escalate to external review if denied.

### Documentation to Gather

• FDA label / indication confirmation: Printout of the Hizentra FDA prescribing information confirming the approved indication (for on-label appeals).
• Diagnosis documentation: Chart notes from the treating specialist (immunologist, neurologist, or other relevant specialist) confirming the diagnosis and clinical rationale for SCIG therapy.
• Specialty society guideline reference: Your prescriber may reference the relevant guideline organization (such as the applicable immunology or neurology society) for its general recommendation on immunoglobulin therapy, without citing specific numbers.
• Compendia support (for off-label use): Reference to a recognized compendia listing if applicable.
• Prescriber medical-necessity letter: Explains why Hizentra is the appropriate agent for this patient's specific condition and why alternatives are inadequate.
• Criteria mapping: Copy each element of Aetna's experimental/investigational criteria; document factually how the drug and its use fail to meet the experimental definition.

### Key Reminder

Retrieve the current version of Aetna's experimental/investigational coverage policy and its immunoglobulin coverage policy directly from Aetna's website or member services. The version in effect on the date of the denied claim controls the appeal — confirm the applicable policy date with Aetna if uncertain.